MONROVIA, Calif., Aug. 15, 2017 /PRNewswire/ -- STAAR Surgical
Company (NASDAQ: STAA) a leading developer, manufacturer and
marketer of implantable lenses and delivery systems for the eye,
and Dr. Jong Ho Lee, Seoul/Busan BalGeunSeSang Eye Clinic today
announced they have entered into an Strategic Cooperation Agreement
to provide STAAR's EVO intraocular lenses (ICL) as a primary and
premium option for patients seeking visual freedom from spectacles
and contact lenses through refractive eye treatment.
"I am very excited that my clinic became a strategic partnership
account with STAAR Surgical Company and I expect to introduce the
ICL to many more patients so they can experience the high quality
of vision in their lives," said Dr. Jong Ho
Lee, President of Seoul/Busan BalGeunSeSang Eye Clinic. "I have
been dedicated to demonstrating the safety and efficacy of the ICL.
Over the last 15 years I have implanted more than 30,000 ICL's in
my clinics. I am proud that our clinics have 13 elite
Ophthalmic Surgeons and more than 150 staff members dedicated to
helping us provide excellent visual results to our patients,"
concluded Dr. Lee.
"STAAR is pleased to have entered into this Strategic
Cooperation Agreement with Dr. Jong Ho
Lee, Seoul/Busan
BalGeunSeSang Eye Clinic. Dr. Lee has been an outstanding
supporter of the ICL and has implanted more ICL's than any other
surgeon. This new level of partnership includes a commitment
to position the ICL as the primary treatment for patients
presenting with minus 8 diopter or above corrections leading to
higher refractive procedure share. We are also providing
co-marketing and digital marketing support of the ICL, training
programs for certified surgeons and staff and new product early
access and development cooperation. STAAR considers strategic
cooperation agreements as fundamental to its transformational goal
to provide outstanding vision care experience and outcomes for
patients with exceptional clinical support as a core tenet," said
Caren Mason, President & CEO of
STAAR.
About STAAR Surgical
STAAR, which has been
dedicated solely to ophthalmic surgery for over 30 years, designs,
develops, manufactures and markets implantable lenses for the eye
with companion delivery systems. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses
are foldable, which permits the surgeon to insert them through a
small incision. STAAR's lens used in refractive surgery is
called an Implantable Collamer® Lens or "ICL". More than
700,000 Visian ICLs, which includes the EVO Visian ICL product
line, have been implanted to date. To learn more about the
ICL go to: www.discovericl.com. STAAR has approximately 340
full-time equivalent employees and markets lenses in over 60
countries. Headquartered in Monrovia, CA, the company operates
manufacturing facilities in Aliso Viejo,
CA and Monrovia, CA.
For more information, please visit the Company's website at
www.staar.com.
Safe Harbor
All statements in this press
release that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: any projections or expectations for sales, marketing and
clinical initiatives, performance of products, and any statements
of assumptions underlying any of the foregoing. Important
additional factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are set forth in the Company's Annual Report on Form 10-K for the
year ended December 30, 2016 under
the caption "Risk Factors," which is on file with the Securities
and Exchange Commission and available in the "Investor Information"
section of the company's website under the heading "SEC
Filings." We disclaim any intention or obligation to update
or revise any financial projections or forward-looking statement
due to new information or events.
These statements are based on expectations and assumptions as of
the date of this press release and are subject to numerous risks
and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking
statements.
CONTACT:
|
Investors &
Media
|
|
EVC Group
|
|
Brian Moore,
310-579-6199
|
|
Doug Sherk,
415-652-9100
|
View original
content:http://www.prnewswire.com/news-releases/staar-surgical-and-seoulbusan-balgeunsesang-eye-clinic-announce-strategic-cooperation-agreement-300504301.html
SOURCE STAAR Surgical Company